Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Tishler AS, de Krijger RR, Gill A, et al.: WHO classification of tumours of the adrenal medulla and extra-adrenal paraganglia. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J. (eds) WHO Classifications of Tumours of Endocrine Organs. 4th edition IARC Press, Lyon, 2017, p. 180-89.
2. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G (2008) EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. Springer Verlag; p. 1039–47
3. Wieland DM, Swanson DP, Brown LE, Beierwaltes WH. Imaging the adrenal medulla with an I-131-labeled antiadrenergic agent. J Nucl Med. 1979;20:155–8.
4. Kinuya S, Yoshinaga K, Higuchi T, Jinguji M, Kurihara H, Kawamoto H. Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors: Guideline Drafting Committee for Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Ann Nucl Med. 2015;29:543–552.
5. Wakabayashi H, Inaki A, Yoshimura K, Murayama T, Imai Y, Higuchi T, et al. (2019) A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Sci Rep 9